Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Go back to Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 3,073,350       

ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 3,073,350       

Daiichi Sankyo Co Limited Sponsored ADR (AMEX: DSNKY) Delayed: 18.01 -0.25 (1.37%)
Previous Close $18.26    52 Week High $26.24 
Open $17.95    52 Week Low $18.86 
Day High $18.04    P/E N/A 
Day Low $17.85    EPS $0.00 
Volume 31,704